Elacridar: A Potent Dual Inhibitor of Breast Cancer Resistance Protein (BCRP) and P-Glycoprotein (P-gp)
Elacridar (GF120918) is a potent dual inhibitor of breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp). BCPR is a member of ATP-binding cassette family of drug transporters. P-gp, known as multidrug resistance protein 1 (MDR1), is an ATP-binding protein of the cell membrane that pumps many foreign substances out of cells. Therefore, it is believed that elacridar increases oral bioavailability of topotecan, a topoisomerase inhibitor. (The product is for research purpose only.)
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.